November 8, 2005
METABOLON APPOINTS DR. MICHAEL MILBURN AS CHIEF SCIENTIFIC OFFICER

RESEARCH TRIANGLE PARK, NC (November 8, 2005) - Metabolon, Inc., a leader in the discovery of biomarkers using metabolomics, today announced the addition of Dr. Michael Milburn as its Chief Scientific Officer. Dr. Milburn was most recently Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals.

“Mike’s extensive background and proven leadership ability in drug discovery and development will be valuable as we continue our biomarker discovery projects and expand our business interest into various phases of product development,” said Dr. John Ryals, president and CEO of Metabolon.

Dr. Milburn brings more than 15 years of experience in biotech and pharmaceutical companies to Metabolon. At Sirtris, he led the preclinical/clinical development of projects in the areas of metabolic disease and neurodegeneration. Prior to Sirtris, Dr. Milburn was Senior Vice President of Research at Plexxikon, where he was responsible for the development of the company’s proprietary high-throughput co-crystallography drug discovery platform. He has also held positions at Structural Genomix and GlaxoSmithKline. Dr. Milburn received his Ph.D. in Structural Chemistry at the University of California, Berkeley, and was a Research Fellow at Harvard Medical School for his postdoctoral work.

“Metabolon is the leading company in the development and application of metabolomics, and I look forward to building on its success,” said Dr. Milburn. “Metabolon’s ability to identify all of the human metabolites within a disease context or drug effect represents a fast path to identifying new disease diagnostics or alternative therapeutic uses for drug candidates.”

About Metabolon
Metabolon is an industry leader in the discovery of biomarkers through the use of metabolomics, a powerful scientific approach for the discovery and development of drugs and the early diagnosis of disease states. Metabolon's patent-pending technology is poised to dramatically impact drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten the time for drugs to get to market and identify novel biomarkers for earlier disease detection. In conjunction with the NIH, Metabolon was honored as a recipient of the 2005 March of Dimes Award for Best Research in Prematurity. For additional information, visit www.metabolon.com.